A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT ID: NCT02157506

Last Updated: 2019-07-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2015-07-31

Brief Summary

A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.

Detailed Description

This is a dose finding, randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure which will first evaluate up to four ascending dose levels of CXL-1427 in up to four cohorts of 8 patients each (the "Dose Escalation" cohorts). Subsequently, up to three of the initial dose levels of CXL-1427 may be assessed in the additional "Expansion" cohorts of up to approximately 16 patients to gain further confidence in the results at these dose levels. The CXL-1427 dose that will be evaluated in the first cohort will be 3µg/kg/min. The dose levels for the next three sequential Dose Escalation cohorts will be dependent on clinical safety and tolerability, as well as the results of the invasive hemodynamic measurements.

Conditions

Heart Failure; Decompensated Heart Failure; Acute Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

CXL-1427 Starting Dose

The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min

Group Type: EXPERIMENTAL

CXL-1427

Intervention Type: DRUG

CXL-1427 Dose Level 2

The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee

Group Type: EXPERIMENTAL

CXL-1427

Intervention Type: DRUG

CXL-1427 Dose Level 3

The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee

Group Type: EXPERIMENTAL

CXL-1427

Intervention Type: DRUG

CXL-1427 Dos Level 3

The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee

Group Type: EXPERIMENTAL

CXL-1427

Intervention Type: DRUG

CXL-1427 Dose Level 4

The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee

Group Type: EXPERIMENTAL

CXL-1427

Intervention Type: DRUG

Expansion Cohort 1

Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee

Group Type: EXPERIMENTAL

CXL-1427

Intervention Type: DRUG

Placebo for Dose Escalation and Expansion Cohort

Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

CXL-1427

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

BMS-986231; 5% Dextrose & 10mM potassium acetate as same IV solution diluents used in active

Eligibility Criteria

Inclusion Criteria

• Be ≥ 18 and ≤ 85 years of age;
• Have a left ventricular ejection fraction (LVEF) ≤40%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) within 3 months prior to or during the current hospitalization;
• Be hospitalized with a primary heart failure or heart failure-related reason, e.g., acute decompensation of heart failure, transplant evaluation, hemodynamic optimization prior to ambulatory inotropes or left ventricular assist device placement;

Exclusion Criteria

• Have a Fick and/or thermodilution determination of cardiac index ≤2.5L/min•m2 at screening, i.e., ≤4 hours before the intended start of the study drug infusion; [Note: For determinations of CI using the thermodilution method, a mean of three consecutive values measured approximately 5 minutes apart, none of which differs from the mean value by more than 15%, should be used.]
• Have a screening and baseline PCWP (or PAD, if a PCWP waveform cannot be reliably obtained) of ≥20 mmHg if systolic blood pressure is ≥100mmHg OR ≥22mmHg if systolic blood pressure is between 95-99mmHg (inclusive);
• Be considered sufficiently stable to be expected not to require administration of any IV or oral vasoactive medications, including diuretics, for at least ~10 hours, i.e., from 4 hours before performing baseline hemodynamic assessments until after the completion of the 6-hour study drug infusion;
• Have a body weight of at least 50kg (110 pounds), but not more than 125kg (275 pounds), and have a body mass index (BMI) <40kg/m2;
• Have adequate peripheral forearm vein access or an available central line port for administration of study drug;
• Be capable of understanding the nature of the trial; be willing and able to comply with the inpatient and outpatient study protocol requirements for the duration of the study (screening period, treatment period, and 30-day post-infusion follow-up period); and be willing to participate in the study, as documented by written informed consent.

• Have a heart rate <50 or >110 beats per minute (bpm) at baseline;
• Have a screening OR baseline systolic blood pressure (SBP) of >150mmHg or <100mmHg, if PCWP ≥ 20mmHg, but <22mmHg OR <95mmHg, if PCWP ≥ 22mmHg;
• Have tricuspid or pulmonary valve prosthesis or endocarditis, right heart mass, a history of pneumothorax or hemothorax, a bleeding diathesis that would preclude placement of a PAL, or a history of complications from previous pulmonary artery catheter placement, when a pulmonary artery catheter is to be placed solely for the purposes of monitoring the hemodynamic effects of the study drug; In this setting, patients with multiple intracardiac leads and/or left bundle branch block should have such elective pulmonary artery catheter placement performed under radiologic guidance by experienced personnel, e.g. in the cardiac catheterization laboratory. [Note: Other pertinent history, such as trauma, vascular injury or previous surgery should guide selection of the vessel for PAL placement.]
• Have a primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy (as defined by any wall thickness > 1.8cm) or uncorrected severe valvular disease as defined by AHA/ACC/ESC criteria;
• Have been treated with dopamine, dobutamine, enoximone, nesiritide, nitroglycerine or nitroprusside within 4 hours, or with levosimendan, amrinone or milrinone within 8 hours, prior to performing baseline hemodynamic assessments, or have an anticipated need to be treated with any of these agents before the completion of the 6-hour study drug infusion;
• Be receiving concomitant parenteral therapy with any antiarrhythmic drugs (oral therapy is allowed);
• Be in atrial fibrillation/flutter with an uncontrolled rate (≥100bpm) at the time of randomization; [Note: Patients with a history of A-fib/flutter are eligible, if heart rate is controlled with a ventricular rate not exceeding 100bpm.]
• Have non-sustained ventricular tachycardia (NSVT) of 10 beats or more during any bedside monitoring within 2 hours prior to randomization, or have excessive premature ventricular contractions (PVCs) or complex multifocal ventricular ectopy exceeding 10 beats per minute on a 2-minute rhythm strip taken within 2 hours prior to randomization;
• Require, or be expected to require, any alteration of settings to an implantable cardioverter-defibrillator (ICD), single chamber or biventricular pacemaker, if applicable, from 2 hours before the intended start of the study drug infusion, until after the completion of the study drug infusion;
• Have a history of sudden cardiac death/resuscitation or other appropriate ICD firing within the past 1 year. (Inappropriate ICD firings are not exclusionary);
• Be hospitalized with acute coronary syndrome or acute myocardial infarction during the previous 90 days prior to randomization;
• Have a history of a cerebral vascular accident (CVA or stroke) or of a transient ischemic attack (TIA) within 6 months prior to randomization;
• Have a digoxin level above 1ng/ml (1.281nmol/L) within 8 hours before initiation of the study drug infusion;
• Have persistent abnormal serum electrolytes at baseline, as defined by: a Na+ concentration <130 or >145 mEq/L, or a K+ or Mg2+ concentration outside the normal range (according to the local laboratory); [Note: Any observed electrolyte abnormalities during screening or earlier should be corrected by electrolyte supplementation and within normal acceptable concentrations should be confirmed prior to dosing. Any serum electrolyte abnormalities with associated clinical instability within 8 hours before initiation of the study drug infusion is exclusionary.]
• Have an ALT or AST >3 times the upper normal limit or a hemoglobin <10g/dl (100g/L) within 8 hours before initiation of the study drug infusion;
• Have a serum creatinine >2.5mg/dl (221µmol/L) or severe renal insufficiency [based on any standard limit and equation employed by the local lab, such as a GFR < 30mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) equation] within 8 hours before initiation of the study drug infusion;
• Have taken an oral phosphodiesterase type 5 inhibitor (PDE5) inhibitor within 96 hours before initiation of the study drug infusion;
• If female, be pregnant or of child-bearing potential (i.e., female patients must be post-menopausal or surgically sterilized);
• Be receiving a drug which is expected to possess a potential for a clinically significant pharmacokinetic interaction with CXL-1427, as defined in the CXL-1427 Investigator's Brochure;
• Be the recipient of a myocardial restraint device or flap;
• Have an anticipated survival of less than 90 days, for any reason;
• Have received an investigational drug, device or biologic product within 30 days (or if longer, 5 half-lives for a drug or biologic agent) prior to randomization, or be planning to receive an investigational agent at any time throughout the full duration of the study until at least 30 days after discontinuation of study drug;
• Have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cardioxyl Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

ShiYin Foo, M.D., Ph D.

Role: STUDY_DIRECTOR

Cardioxyl Pharmaceuticals

Locations

Cardioxyl Study Site

Gainesville, Florida, United States

Cardioxyl Study Site

Jacksonville, Florida, United States

Cardioxyl Study Site

Jacksonville, Florida, United States

Cardioxyl Study Site

Macon, Georgia, United States

Cardioxyl Study Site

Baltimore, Maryland, United States

Cardioxyl Study Site

Detroit, Michigan, United States

Cardioxyl Study Site

Newark, New Jersey, United States

Cardioxyl Study Site

Chapel Hill, North Carolina, United States

Cardioxyl Study Site

Cincinnati, Ohio, United States

Cardioxyl Study Site

Columbus, Ohio, United States

Cardioxyl Study Site

Charleston, South Carolina, United States

Cardioxyl Study Site

Nashville, Tennessee, United States

Cardioxyl Study Site

Salt Lake City, Utah, United States

Cardioxyl Study Site

Richmond, Virginia, United States

Cardioxyl Study Site

Bad Neuheim, , Germany

Cardioxyl Study Site

Cologne, , Germany

Cardioxyl Study Site

Frankfurt, , Germany

Cardioxyl Study Site

Göttingen, , Germany

Cardioxyl Study Site

Greifswald, , Germany

Cardioxyl Study Site

Kiel, , Germany

Cardioxyl Study Site

Regensberg, , Germany

Cardioxyl Study Site

Amman, , Jordan

Cardioxyl Study Site

Irbid, , Jordan

Cardioxyl Study Site

Lodz, , Poland

Cardioxyl Study SIte

Warsaw, , Poland

Cardioxyl Study Site

Warsaw, , Poland

Cardioxyl Study Site

Wroclaw, , Poland

Cardioxyl Study Site

Kemerovo, , Russia

Cardioxyl Study Site

Moscow, , Russia

Cardioxyl Study Site

Moscow, , Russia

Cardioxyl Study Site

Moscow, , Russia

Cardioxyl Study Site

Moscow, , Russia

Cardioxyl Study Site

Saint Petersburg, , Russia

Cardioxyl Study Site

Saint Petersburg, , Russia

Cardioxyl Study Site

Tomsk, , Russia

Countries

United States; Germany; Jordan; Poland; Russia

Other Identifiers

CV013-006

Identifier Type: OTHER

Identifier Source: secondary_id

CXL-1427-02

Identifier Type: -

Identifier Source: org_study_id